Mineral metabolism, mortality, and morbidity in maintenance hemodialysis.

By G. Block, P. Klassen, J. Lazarus, N. Ofsthun, E. Lowrie, Glenn M. Chertow. Journal of the American Society of Nephrology, 2004

2,685 citations recorded by the source corpus.

Subfields: Nephrology, Pediatrics, Perinatology and Child Health

View Paper: https://www.semanticscholar.org/paper/be72f7d9a1ebab775ad8e18318b5c6894cd0c0ab

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Nephrology

1. A. Levin
2. R. Mehta

Citations in the corpus

• Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. (2006, methodology): “Higher serum calcium and phosphorus levels were consistently associated with increased death risks, which is consistent with recent findings by Block et al.(7,10) and other investigators who used non-time-dependent models.”
• Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. (2005, background): “It is biologically plausible that the relation between bone turnover and serum calcium underlies the recent report of an association between higher adjusted serum calcium and mortality in patients on hemodialysis [18].”
• Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. (2005, methodology): “Therefore, we performed this cross-sectional study of patients from across the entire spectrum of predialysis CKD to test the following hypotheses: (1) FGF-23 levels increase with advancing stages of CKD; (2) the rise in FGF-23 levels and the reduction in calcitriol levels precede the development of”
• KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) (2009, neutral): “36 (NS); Mean whole (1-84) PTH (pmol/L): 17.”
• Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. (2011, background): “In most patients, this hypocalcemia is easily managed with dose adjustment (78) or a combination with low doses of vitamin D sterols in subjects with moderate to severe SHPT (79).”
• Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. (2007, background): “Elevated PTH and hyperphosphatemia were recently identified again as risk factors for mortality in dialysis patients.(10) However, additional data indicate that vitamin D treatment is an important factor that may mitigate the effects of HPTH and hyperphosphatemia on cardiovascular mortality.”